Mallinckrodt to present at Jefferies 2016 London Healthcare Conference

CHESTERFIELD, England, Oct. 26, 2016 /PRNewswire/ -- Mallinckrodt Pharmaceuticals (NYSE: MNK), a leading global specialty pharmaceutical company, will present on Thursday, Nov. 17, 2016, at the Jefferies Global Healthcare Conference at The Waldorf Hilton, London, Aldwych, London, WC2B 4DD, United Kingdom.

Cole Lannum, Senior Vice President, Investor Strategy and IRO, and Daniel Speciale, Director, Investor Relations, will represent the company in a presentation and Q&A session at 2:40 p.m. GMT.

Individuals who cannot attend the meeting in person can find webcast information at: http://www.mallinckrodt.com/investors. A replay will also be available following the meeting.

ABOUT MALLINCKRODTMallinckrodt is a global business that develops, manufactures, markets and distributes specialty pharmaceutical and biopharmaceutical products and therapies, as well as nuclear imaging products. Areas of focus include autoimmune and rare diseases in specialty areas like neurology, rheumatology, nephrology, pulmonology and ophthalmology; immunotherapy and neonatal respiratory critical care therapies; analgesics and hemostasis products; and central nervous system drugs. The company's core strengths include the acquisition and management of highly regulated raw materials and specialized chemistry, formulation and manufacturing capabilities. The company's Specialty Brands segment includes branded medicines; its Specialty Generics segment includes specialty generic drugs, active pharmaceutical ingredients and external manufacturing; and the Nuclear Imaging segment includes nuclear imaging agents. To learn more about Mallinckrodt, visit www.mallinckrodt.com.

Mallinckrodt uses its website as a channel of distribution of important company information, such as press releases, investor presentations and other financial information. It also uses its website to expedite public access to time-critical information regarding the company in advance of or in lieu of distributing a press release or a filing with the U.S. Securities and Exchange Commission disclosing the same information. Therefore, investors should look to the Investor Relations page of the website for important and time-critical information. Visitors to the website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations page of the website.

CONTACTS

Investor RelationsColeman N. Lannum, CFASenior Vice President, Investor Strategy and IRO314-654-6649[email protected]

Daniel J. Speciale, CPADirector, Investor Relations314-654-3638[email protected]

MediaRhonda SciarraSenior Communications Manager908-238-6765[email protected]

Meredith FischerChief Public Affairs Officer314-654-3318[email protected]

Logo - http://photos.prnewswire.com/prnh/20150105/167103LOGO

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mallinckrodt-to-present-at-jefferies-2016-london-healthcare-conference-300351595.html

SOURCE Mallinckrodt Pharmaceuticals